Completed PHASE2 INTERVENTIONAL NCT00612183

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-label Study)

Sponsor: SymBio Pharmaceuticals

Conditions Mantle Cell Lymphoma Non-Hodgkin's Lymphoma

Interventions bendamustine hydrochloride

Updated 6 times since 2017 Last updated: Jul 21, 2010 Started: Dec 31, 2007 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma and is currently completed. SymBio Pharmaceuticals leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SymBio Pharmaceuticals

Data source: SymBio Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chūō, Japan , Fukuoka, Japan , Hamamatsu, Japan , Isehara, Japan , Kagoshima, Japan , Kashiwa, Japan , Koto, Japan , Kumamoto, Japan , Kyoto, Japan , Moriguchi, Japan and 6 more locations